Healthcare

Healthcare sector stocks including pharmaceuticals, biotechnology, and medical devices.

63 articles

Healthcare | PFE | 1w ago

Deep Dive: API Market Growth Reshapes Outlook for PFE

PFE stands to benefit from the API market's projected growth to USD 198.39 billion by 2030, driven by oncology and diabetes advancements.

Healthcare | NTRA | 1w ago

After Natera Inc. Announces Q4 Earnings Date, Where Does NTRA Go Next?

Natera Inc. (NTRA) is poised to announce its Q4 results soon. Here's what investors should watch leading up to this critical date.

Healthcare | CVS | 1w ago

CVS Health Rallies on Transformative Retail Pharmacy Strategy

CVS Health is transforming its retail pharmacies into comprehensive health hubs, focusing on preventive care and expanding its diverse product offerings.

Healthcare | LLY | 1w ago

Eli Lilly Stands Out After JPMorgan Chase's $2.93B Investment

A significant $2.93 billion investment from JPMorgan Chase into Eli Lilly (LLY) demonstrates strong confidence in its future growth potential.

Healthcare | SYK | 1w ago

Market Growth Surge: Stryker Corp. Taps into $5.31B Opportunity

Stryker Corp. (SYK) is poised to leverage the booming clinical communication market, projected to hit $5.31 billion by 2030.

Healthcare | SYK | 1w ago

Stryker Corp. Gains Steam After Strong Q4 Revenue Beat

SYK's latest quarterly results topped expectations, showcasing impressive growth in key segments. Analysts are optimistic about Stryker Corp.'s future trajectory.

Healthcare | NTLA | 1w ago

NTLA Climbs After H.C. Wainwright Boosts Price Target to $25

Intellia Therapeutics (NTLA) sees a surge in analyst confidence as H.C. Wainwright raises its price target to $25, spurring investor interest.

Healthcare | HALO | 1w ago

Breaking: Halozyme Therapeutics Reports $1.3B in Acquisitions

HALO makes headlines with its substantial $1.3 billion investment in three biotech acquisitions, reshaping its market position. Find out more.

Healthcare | ELV | 1w ago

Decoding Elevance Health's Response to Low Volatility Concerns

ELV’s low volatility may seem stable, but it raises questions about long-term performance. How does Elevance Health balance risk and reward?

Healthcare | GSK | 1w ago

GSK Jumps on Fourth-Quarter Earnings Beat News

GSK's fourth-quarter earnings beat expectations with strong revenue and EPS, making it a stock to watch in today's market.

Healthcare | GEHC | 2w ago

ReadyFix Launch Puts GEHC in the Spotlight as Investors React

GEHC's recent launches of ReadyFix and Allia Moveo highlight its growth strategy, stirring investor interest and market reactions.

Healthcare | GEHC | 2w ago

Dividend Declaration Becomes Key Catalyst for GEHC

GEHC shares are set to benefit as the company announces a $0.035 cash dividend for Q1 2026, enhancing investor confidence.

Healthcare | ALNY | 2w ago

Alnylam Pharmaceuticals Price Target Cut Sparks Debate Over ALNY

Bank of America has revised its price target for Alnylam Pharmaceuticals to $462. What does this mean for ALNY investors?

Healthcare | RARE | 2w ago

Ultragenyx Pharmaceutical Rallies as UX111 Data for Sanfilippo Unfolds

Ultragenyx Pharmaceutical (RARE) is in the spotlight following robust data on its gene therapy UX111, signaling significant progress for Sanfilippo syndrome.

Healthcare | RXRX | 2w ago

Is Recursion Pharmaceuticals Overvalued After 57.9% Decline?

Recursion Pharmaceuticals (RXRX) has experienced a 57.9% stock decline over the past year, raising valuation concerns. What does this mean for investors?

Healthcare | WAT | 2w ago